Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,561 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the transaction, the chief marketing officer now owns 13,537 shares of the company’s stock, valued at approximately $3,454,236.29. This trade represents a 10.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Trading Down 2.5 %

Shares of ALNY opened at $250.00 on Wednesday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a 50-day moving average price of $253.96 and a 200 day moving average price of $263.29. The firm has a market capitalization of $32.25 billion, a P/E ratio of -95.42 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Analyst Ratings Changes

ALNY has been the topic of several research analyst reports. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Chardan Capital reissued a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. Finally, Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $299.48.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently modified their holdings of ALNY. Focus Partners Advisor Solutions LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $203,000. Worldquant Millennium Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 156.6% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after buying an additional 91,671 shares during the period. Zurich Insurance Group Ltd FI purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $6,583,000. Vident Advisory LLC boosted its stake in Alnylam Pharmaceuticals by 21.2% during the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 232 shares during the period. Finally, Soleus Capital Management L.P. boosted its stake in Alnylam Pharmaceuticals by 29.3% during the fourth quarter. Soleus Capital Management L.P. now owns 76,800 shares of the biopharmaceutical company’s stock worth $18,072,000 after buying an additional 17,400 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.